Možnosti využití komplexní farmaceutické kompozice pro farmakologickou korekci metabolického syndromu

Stáhnout PDF English version

Autoři: Kateryna Kalko ¹; Nadia Dukhnich ²; Oksana Mishchenko ²; Viktor Khomenko ³; Olena Toziuk ⁴
Působiště autorů: Department of Pharmacology and Drug Technology of I. I. Mechnikov Odesa National University ¹; Department of Clinical Pharmacology of the National University of Pharmac, Kharkiv, Ukraine ²; Department of Pharmacology and Pharmacy of the Donetsk National Medical University, Lyman, Ukraine ³; Department of Pharmacy, National Pirogov Memorial Medical University, Vinnytsya, Ukraine ⁴
Vyšlo v časopise: Čes. slov. Farm., 2023; 72, 287-296
Kategorie: Původní práce
doi: https://doi.org/10.5817/CSF2023-6-287

Souhrn

Metabolický syndrom (MetS) je symptomatický komplex charakterizovaný inzulinovou rezistencí, poruchou prooxidačně-antioxidační rovnováhy organismu s rozvojem subchronického zánětu a dyslipidemií. Cílem studie je prozkoumat vlivkomplexní farmaceutické kompozice (CPC) (antioxidanty a metabolitotropní látky), která se v lékařské praxi na Ukrajině široce používá jako multivitaminový komplex, na experimentální metabolický syndrom u potkanů. Byl hodnocen vliv CPC na korekci experimentálního MetS u potkanů, vyvolaného vysokým obsahem sacharidů a tuků ve stravě. MetS u potkanů byl charakterizován snížením citlivosti buněk na inzulin, zvýšeným obsahem glukózy a porušením její utilizace, a prooxidačně-antioxidační dysbalancí. Výsledky provedených studií naznačují pozitivní vliv CPC, který obsahuje etylestery omega-3 kyselin, vitamin E, koenzym Q10, zinek, vitamin A, biotin a selen, na citlivost buněk k inzulinu, utilizaci glukózy, trvání hyperglykémie a ukazatele oxidačních procesů volných radikálů a antioxidačníchobranných systémů u potkanů s experimentálním MetS. Tyto výsledky dokazují možnost využití CPC k korekci metabolického syndromu.

Klíčová slova:

metabolický syndrom – hyperglykemie – citlivost buněk na inzulin – prooxidačně-antioxidační rovnováha

Zdroje

Bovolini A, Garcia J, Andrade MA, Duarte JA. Metabolic Syndrome Pathophysiology and Predisposing Factors. Int. J. Sports Med. 2021; 42(3), 199–214. doi: 10.1055/a-1263-0898
Kalko K. O. «Korvitin®» – new therapeutic opportunities Pharmacologyonline 2021; 2, 1310–1316. Avaiable from:https://pharmacologyonline.silae.it/files/archives/2021/ vol2/PhOL_2021_2_A144_Kalko.pdf
Gurka MJ, Guo Y, Filipp SL, DeBoer MD. Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes. Cardiovasc. Diabetol. 2018; 17, 17. doi: 10.1186/s12933-017-0647-y
Lopez-Candales A, Hernández Burgos PM, Hernandez-Suarez DF, Harris D. Linking chronic inflammation with cardiovascular disease: From normal aging to the metabolic syndrome. J. Nat. Sci. 2017; 3, e341
Castillo-Díaz LA, Ruiz-Pacheco JA, Elsawy MA, ReyesMartínez JE, Enríquez-Rodríguez AI. Self-Assembling Peptides as anEmerging Platform for the Treatment of Metabolic Syndrome. Int. J. Nanomedicine 2020; 15, 10349–10370. doi: 10.2147/IJN.S278189
Carrier A. Metabolic Syndrome and Oxidative Stress: A Complex Relationship. Antioxid. Redox Signal 2017; 26(9), 429–431. doi: 10.1089/ars.2016.6929
McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin. Dermatol 2018; 36(1), 14–20. doi: 10.1016/j.clindermatol.2017.09.004
Gregório BM, De Souza DB, de Morais Nascimento FA, Pereira LM, Fernandes-Santos C. The potential role of antioxidants in metabolic syndrome. Curr. Pharm. Des. 2016; 22(7), 859–869. doi: 10.2174/13816128226661512 09152352
Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv. Nutr. 2014; 5(4), 404–417. doi: 10.3945/ an.113.005603.
Dludla PV, Nyambuya TM, Orlando P, Silvestri S, Mxinwa V, Mokgalaboni K, Nkambule BB, Louw J, Muller CJF, Tiano L. Theimpact of coenzyme Q10 on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta-analysis of randomized controlled trials. Endocrinol. Diabetes Metab. 2020; 3(2), e00118. doi: 10.1002/edm2.118
Dakshinamurti K. Vitamins and their derivatives in the prevention and treatment of metabolic syndrome diseases (diabetes). Can J. Physiol. Pharmacol. 2015; 93(5), 355–362. doi: 10.1139/cjpp-2014-0479
Beydoun MA, Chen X, Jha K, Beydoun HA, Zonderman AB, Canas JA. Carotenoids, vitamin A, and their association with the metabolic syndrome: a systematic review and meta-analysis. Nutr. Rev. 2019; 77(1), 32–45. doi: 10.1093/nutrit/nuy044
Farajbakhsh A, Mazloomi SM, Mazidi M, Rezaie P, Akbarzadeh M, Ahmad SP, Ferns GA, Ofori-Asenso R, Babajafari S. Sesame oil and vitamin E co-administration may improve cardiometabolic risk factors in patients with metabolic syndrome: a randomized clinical trial. Eur. J. Clin. Nutr. 2019; 73(10), 1403–1411. doi: 10.1038/ s41430-019-0438-5
Directive 2010/63/EU of the European Parliament and of the Council of September 22 2010 on the protection of animals used for scientific purposes. Official Journal of the European Union 2010; 33–79.
AEVIT PREMIUM: instructions for medical use [Electronic resource] – Access mode: https://compendium.com.ua/ info/350158/aevit-premium/
Siofor: instructions for medical treatment [Electronic resource] – Access mode: https://mozdocs.kiev.ua/likiview. php?id=38861
Vitamin E instructions for medical treatment [Electronic resource] – Access mode: https://www.lekhim.ua/ru/alfa-tokoferola-acetat-vitamin-e_dose-100-mgml-po-20ml-no-1
Kalko K. O., Drogovoz S. M., Mishchenko O. Ya., Komisarenko M. A., Komissarenko A. M., Bondariev Y. V., Moeen Dababneh. Administration of «CORVITIN®» as an off-label agent for pharmacological correction of metabolic syndrome. Problems of endocrine pathology 2021; 1, 97–102. https://www.jpep.endocrinology.org.ua/index.php/1/article/view/124
Rybolovlev Yu. R., Sidlyarov D. P., Afonin N. I. Predictive assessment of the safety of substances for humans by the constants oftheir biological activity. Toxicological aspects of the safety of finished dosage forms: astract report scientific conf. Moscow, December 16–18, 1981. M., 1981. P. 9–10.
Geddawy A, Hussian M, Kamel MY, Kamal R, Ibrahim MA. Effects of Liraglutide and Vitamin E in Fructose-Induced MetabolicSyndrome in Rats. Pharmacology 2017; 9 (1–2), 48-56. doi: 10.1159/000449429.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulinresistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28, 412–419.
Stefanov O. V. Preclinical studies of drugs (methodological recommendations). For order. Corresponding Member NAMS of Ukraine Kyiv: VD Avicenna, 2001.
Truhacheva N. V. Mathematical statistics in medical-biological researches using the package statistics. Moscow, Russian Federation: GEOTAR-Media 2012.
Russo B, Picconi F, Malandrucco I, Frontoni S. Flavonoids and Insulin-Resistance: From Molecular Evidences to Clinical Trials. Int. J. Mol. Sci. 2019; 20(9), 2061. doi: 10.3390/ijms20092061
Dakshinamurti K. Vitamins and their derivatives in the prevention and treatment of metabolic syndrome diseases (diabetes). Can. J. Physiol. Pharmacol. 2015; 93(5), 355–362. doi: 10.1139/cjpp-2014-0479
Albracht-Schulte K, Kalupahana NS, Ramalingam L, Wang S, Rahman SM, Robert-McComb J, Moustaid-Moussa N. Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. J. Nutr. Biochem. 2018; 58, 1–16. doi:10.1016/j.jnutbio.2018.02.012
Tortosa-Caparrós E, Navas-Carrillo D, Marín F, Orenes-Piñero E. Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome. Crit. Rev. Food. Sci. Nutr. 2017; 57(16), 3421–3429. doi: 10.1080/10408398.2015.1126549
Kawada T. Omega-3 polyunsaturated fatty acids and metabolic syndrome. Clin. Nutr. 2020; 39(7), 2319. doi:10.1016/j.clnu.2020.05.033
Geddawy A, Hussian M, Kamel MY, Kamal R, Ibrahim MA. Effects of Liraglutide and Vitamin E in Fruc tose-Induced MetabolicSyndrome in Rats. Pharmacology. 2017; 99(1–2), 48–56. doi: 10.1159/000449429
Zozina VI, Covantev S, Goroshko OA, Krasnykh LM, Kukes VG. Coenzyme Q10 in Cardiovascular and Metabolic Diseases:Current State of the Problem. Curr. Cardiol. Rev. 2018; 14(3), 164–174. doi: 10.2174/1573403X146 66180416115428
Dludla PV, Orlando P, Silvestri S, Marcheggiani F, Cirilli I, Nyambuya TM, Mxinwa V, Mokgalaboni K, Nkambule BB, Johnson R, Mazibuko-Mbeje SE, Muller CJF, Louw J, Tiano L. Coenzyme Q10 Supplementation Improves Adipokine Levels and Alleviates Inflammation and Lipid Peroxidation in Conditions of Metabolic Syndrome: A Meta-Analysis of RandomizedControlled Trials. Int. J. Mol. Sci. 2020; 21(9), 3247. doi: 10.3390/ijms21093247.
Aguilera-Mendez A, Hernández-Equihua MG, Rueda-Rocha AC, Guajardo-López C, Nieto-Aguilar R, Serrato-Ochoa D, Ruíz Herrera LF, Guzmán-Nateras JA. Protective effect of supplementation with biotin against high-fructose-induced metabolic syndromein rats. Nutr. Res. 2018; 57, 86–96. doi: 10.1016/j.nutres.2018.06.007
Miao X, Sun W, Fu Y, Miao L, Cai L. Zinc homeostasis in the metabolic syndrome and diabetes. Front. Med. 2013; 7(1), 31–52. doi: 10.1007/s11684-013-0251-9
Aguilera-Mendez A, Hernández-Equihua MG, Rueda-Rocha AC, Guajardo-López C, Nieto-Aguilar R, Serrato-Ochoa D, Ruíz Herrera LF, Guzmán-Nateras JA. Protective effect of supplementation with biotin against high-fructose-induced metabolic syndrome in rats. Nutr. Res. 2018; 57, 86–96. doi: 10.1016/j. nutres.2018.06.007
Retondario A, Fernandes R, Rockenbach G, Alves MA, Bricarello LP, Trindade EBSM, Vasconcelos FAG. Selenium intake and metabolic syndrome: A systematic review. Clin. Nutr. 2019; 38(2), 603–614. doi: 10.1016/j. clnu.2018.02.021
Beydoun MA, Chen X, Jha K, Beydoun HA, Zonderman AB, Canas JA. Carotenoids, vitamin A, and their association with the metabolic syndrome: a systematic review and meta-analysis. Nutr. Rev. 2019; 7(1), 32–45. doi: 10.1093/nutrit/nuy044.